This confounding makes it difficult to determine whether any observed risk is due to the medication or underlying patient characteristics
Average weight loss with Contrave is approximately 5-8% of body weight, lower than tirzepatide but meaningful for people whose weight gain is driven by emotional eating, food addiction, or reward-seeking behavior patterns
Buchwald et al., 2004), and the inhibition of glucagon-secreting pancreatic -cells (Holst, 2004), and decreasing gastrointestinal motility (Meier et al., 2003) and body weight (Larsen et al., 2001)
The digestive system does not recognize it as a hormone
Somatotopic organization and intensity dependence in driving distinct NPY-expressing sympathetic pathways by electroacupuncture
After the infusion, the IV line is removed, and the insertion site is checked